Aktieinformation ANI Pharmaceuticals | Filter  Basic-Info

ANI Pharmaceuticals

The past year was a good year for ANI Pharmaceuticals investors

Over the period from December 2015 till December 2016 the stock gained around 41 percent. Over the past 5 years ANI Pharmaceuticals' stock rose at around 278 percent in value. ANI Pharmaceuticals's revenues between 2011 and 2015 were quite unstable and moved between 2,3 million dollars and 76,32 million dollars. The net results between 2011 and 2015 were far from constant and fluctuated between -51,61 million dollars and 15,38 million dollars.

The headquarter of ANI Pharmaceuticals is based in Baudette. ANI Pharmaceuticals is mostly active in the pharmaceutical sector. ANI Pharmaceuticals is leaded by CEO Mr. Arthur S. Przybyl The CFO of ANI Pharmaceuticals the company is Ms. Charlotte C. Arnold CPA. The past 10 years the (international) industry gained at around 75 percent. Measured since 2011 the sector is 147 percent higher and over the past 12 months (December 2015-December 2016) there is a minus of 75 percent.

Over the past 5 years the American company paid out dividends.

ANI Pharmaceuticals' balance mostly financed with equity

At the end of 2015 the American company had a balance sheet of 285,27 million dollars. At the end of 2015 the total debt positon equaled 125,19 million dollars. This is around 43,88 percent of the total balance sheet. At the end of 2015 the pharmaceutical company's stock was traded with a price/earnings-ratio 42. So the stock' value was 42 times the 2015' earnings per share. Based on it's price/earnings-ratio and dividend yield the American stock can be seen as a growth stock.

At the end of 2015 the American company's market capitalization equaled around 497,32 million dollars. At the end of 2015 the American company had around 11,37 million stocks listed.

All ANI Pharmaceuticals's annual reports can be found here. More information about ANI Pharmaceuticals can be found it's website. .